Cardiovascular risk and the thiazolidinediones: Déjà vu all over again?

JAMA

Volumn 298, Issue 10, 2007, Pages 1216-1218

  Solomon, Daniel H ^a,b   Winkelmayer, Wolfgang C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Division of Rheumatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; ANTIDIABETIC AGENT;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; VASCULAR DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK; THIAZOLIDINEDIONES;

EID: 34548588959     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.10.1216     Document Type: Editorial

References (11)

1. Brown JD, Pluzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518-533.
2. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941-2948.
3. US Food and Drug Administration. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk: companies will include boxed warning on drug label [press release]. August 14, 2007. http://www.fda.gov/bbs/topics/ NEWS/2007/NEW01683.html. Accessed August 15, 2007.
4. Dormandy JA, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
5. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med. 2007;357(1):28-38.
6. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
7. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-1195.
8. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-1188.
9. US Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held on July 30, 2007. http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007- 4308m1-final.pdf. Accessed August 15, 2007.
10. Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA. 2000;284(23):3036-3039.
11. Manns B, Owen WF Jr, Winkelmayer WC, Dveraux PJ, Tonelli M. Surrogate markers in clinical studies: problems solved or created? Am J Kidney Dis. 2006;48(1):159-166.